Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dileucine is a dipeptide consisting of two leucine molecules (L-leucyl-L-leucine monohydrate) designed to enhance muscle protein synthesis (MPS) and combat sarcopenia. Unlike free leucine, dileucine is transported into the intestinal endothelium via the high-capacity peptide transporter 1 (PEPT1), leading to faster and more efficient absorption. Research indicates that dileucine significantly increases intramuscular leucine availability and triggers the mTORC1 anabolic signaling pathway more effectively than an equivalent dose of free leucine. It is being developed as a low-volume nutritional intervention to overcome anabolic resistance in aging populations and to improve strength and muscular endurance in resistance-trained individuals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dileucine.